PDCD1 and hepatocellular carcinoma: reported that anti-PD-1 drug significantly improves the response for HCC and offers mechanistic insights into the immune trajectories in different immune subsets, indicating that immunotherapy targeting inhibitory immune checkpoints is promising in HCC (41).